Status:
RECRUITING
Conversion From Unresectable To Resectable Metastatic Colorectal Cancer.
Lead Sponsor:
University of Saskatchewan
Conditions:
Metastatic Colorectal Cancer
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
Most patients with mCRC are treated with palliative chemotherapy and only a small number of patients with limited metastatic disease achieve long-term remission following metastasectomy. There is a gr...
Detailed Description
Colorectal cancer is the second leading cause of cancer-related death in North America. Patients with metastatic colorectal cancer generally have limited life expectancy, however, a small number of pa...
Eligibility Criteria
Inclusion
- Adult patients, aged between 18 and 70 years with histologically proven adenocarcinoma or poorly differentiated carcinoma of the colon and rectum with unresectable liver-only metastases and no extra-hepatic disease.
- World Health Organization (WHO) performance status of 0-1.
- No previous chemotherapy for advanced disease.
- Adequate functioning of the bone marrow, liver, and kidneys.
Exclusion
- Breastfeeding or pregnancy.
- An active second primary cancer with the exception of squamous cell carcinoma of the skin or an in situ cancer.
- Severe or uncompensated concomitant medical conditions.
Key Trial Info
Start Date :
May 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT03401294
Start Date
May 1 2025
End Date
December 31 2026
Last Update
May 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Allan Balir Cancer Center
Regina, Saskatchewan, Canada